S
Silence Therapeutics Plc D
D
SLN
6.21000
USD
0.71
(12.91%)
Market Closed
Volume
18,256
EPS
-1
Div Yield
-
P/E
-5
Market Cap
293,086,654
Title: Silence Therapeutics Plc
Sector: Healthcare
Industry: Biotechnology
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.